Actively Recruiting
Real-World Observational Study on Etrasimod for Adults With Moderate to Severe Ulcerative Colitis
Led by Pfizer · Updated on 2026-10-26
300
Participants Needed
29
Research Sites
40 weeks
Total Duration
AI-Summary
What This Trial Is About
This observational study aims to understand the effects of etrasimod as a treatment for adults with moderate to severe ulcerative colitis who have not taken etrasimod before. Patients will receive etrasimod as part of their usual care, with treatment decisions made by their doctors based on what is best for each patient. Participants will be prescribed etrasimod according to standard medical practice. During the 52-week study period, patients will complete health questionnaires about ulcerative colitis symptoms using a mobile phone, tablet, or computer. Usual tests and doctor visits will follow standard care. After the 52 weeks, there will be a 28-day safety follow-up. Researchers will compare each patients disease activity before and after starting etrasimod, focusing on the proportion of patients who achieve symptom remission at 12 weeks as the main outcome. Additional outcomes include symptom responses and remission at later time points, changes in fatigue, bowel urgency, and abdominal pain. Patients will be monitored through regular questionnaires and standard medical visits throughout the study period.
CONDITIONS
Brief Title
An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here